

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2013

TECHNE CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Minnesota 0-17272 41-1427402

(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
Of Incorporation) Identification
Number)

614 McKinley Place NE
Minneapolis, MN 55413

(Address of Principal Executive Offices) (Zip Code)

(612) 379-8854

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On December 30, 2013, Gregory J. Melsen informed Techne Corporation (the "Company") of his decision to resign from the positions of Vice President of Finance and Chief Financial Officer of the Company, effective as of February 3, 2014.

A copy of the press release announcing Mr. Melsen's resignation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release, dated January 2, 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TECHNE CORPORATION

Date: January 2, 2014 By: /s/ Charles R. Kummeth

Charles R. Kummeth
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release, dated January 2, 2014.

TECHNE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER GREGORY MELSEN

Minneapolis, Minnesota - January 2, 2014 - Techne Corporation (NASDAQ: TECH) today announced that Gregory J. Melsen will resign from his position as Chief Financial Officer, effective February 3, 2014, to pursue other opportunities. Mr. Melsen has served as Techne's Chief Financial Officer since 2004.

Techne has begun the process of identifying a successor to Mr. Melsen and expects to announce the appointment of such successor in the coming months.

"I would like to thank Greg for his immense contributions to Techne during the past nine years," stated Charles Kummeth, President and Chief Executive Officer of Techne. "Greg was instrumental in the recent leadership transition, and the experienced financial team that Greg has put in place will ensure that the current transition is seamless. On behalf of Techne, I wish Greg all the best for the future."

Mr. Melsen said, "Being Chief Financial Officer of Techne has been a great professional experience, and I look forward to watching the Company continue to execute the strategies that have recently been put into place."

About Techne Corporation

Techne Corporation and Subsidiaries (the Company) are engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted through the Company's two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England.

R&D Systems is a specialty manufacturer of biological products. R&D Systems has four subsidiaries: BiosPacific, Inc. (BiosPacific), located in Emeryville, California, Boston Biochem, Inc., located in Cambridge, Massachusetts, Bionostics Holdings Limited (Bionostics), operating in Devens, Massachusetts, and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. Boston Biochem is a leading developer and manufacturer of ubiquitin-related research products. Bionostics is a leading supplier of control solutions used in point of care blood glucose and blood gas testing.

R&D China and R&D Europe distribute the Company's biotechnology products. R&D Europe has two subsidiaries: Tocris Holdings Ltd. (Tocris) of Bristol, England and R&D Systems GmbH, a German sales operation. Tocris is a leading supplier of chemical reagents for non-clinical life science research.

Forward-Looking Statements

Certain statements found in this release may constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect the speaker's current views with respect to future events and financial performance and include any statement that does not directly relate to a current or historical fact. Forward-looking statements can generally be identified by the words "believe," "expect," "anticipate" or "intend" or similar words. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the integration of new leadership, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we

make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Contact
Charles Kummeth
Chief Executive Officer
Techne Corporation
(612) 379-8854